Restricted accessBrief reportFirst published online 2022-08-30
Correlation Between Plasma Oligomeric Amyloid-β and Performance on the Language Neutral Visual Cognitive Assessment Test in a Southeast Asian Population
Oligomeric amyloid-β (OAβ), an upstream driver of Alzheimer’s disease (AD) neuropathology, correlates with poor cognitive performance and brain volume reduction. Its effect on cognitive performance measured by the language neutral Visual Cognitive Assessment Test (VCAT) remains to be evaluated. We studied the correlation of plasma OAβ with VCAT scores and grey matter volume (GMV) in a Southeast Asian cohort with mild cognitive impairment. Higher plasma OAβ significantly correlated with lower; cognitive scores (VCAT, Mini-Mental State Examination) and GMV/intracranial volume ratio. Such findings reveal the clinical utility of plasma OAβ as a promising biomarker and support validation through longitudinal studies.
(2021) 2021 Alzheimer’s disease facts and figures. Alzheimers Dement17, 327–406.
2.
MengX, LiT, WangX, LvX, SunZ, ZhangJ, SuF, KangS, KimS, AnSSA, YuX, ZhangC, WangH (2019) Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease. Alzheimers Res Ther11, 89.
3.
TolarM, HeyJ, PowerA, AbushakraS (2021) Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci22, 6355.
4.
WangMJ, YiS, HanJY, ParkSY, JangJW, ChunIK, KimSE, LeeBS, KimGJ, YuJS, LimK, KangSM, ParkYH, YounYC, AnSSA, KimS (2017) Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease. Alzheimers Res Ther9, 98.
5.
YounYC, KangS, SuhJ, ParkYH, KangMJ, PyunJM, ChoiSH, JeongJH, ParkKW, LeeHW, AnSSA, DominguezJC, KimS (2019) Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease. Alzheimers Res Ther11, 40.
AnSSA, LeeB-S, YuJS, LimK, KimGJ, LeeR, KimS, KangS, ParkYH, WangMJ, YangYS, YounYC, KimS (2017) Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimers Res Ther9, 86.
8.
Babapour MofradR, ScheltensP, KimS, KangS, YounYC, AnSSA, TomassenJ, van BerckelBNM, VisserPJ, van der FlierWM, TeunissenCE (2021) Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimers Res Ther13, 133.
9.
KandiahN, ZhangA, BautistaDC, SilvaE, TingSK, NgA, AssamP (2016) Early detection of dementia in multilingual populations: Visual Cognitive Assessment Test (VCAT). J Neurol Neurosurg Psychiatry87, 156–160.
10.
LimL, NgTP, OngAP, TanMP, CeninaAR, GaoQ, NgA, KandiahN (2018) A novel language-neutral Visual Cognitive Assessment Test (VCAT): Validation in four Southeast Asian countries. Alzheimers Res Ther10, 6.
11.
LowA, LimL, LimL, WongB, SilvaE, NgKP, KandiahN (2020) Construct validity of the Visual Cognitive Assessment Test (VCAT)-a cross-cultural language-neutral cognitive screening tool. Int Psychogeriatr32, 141–149.
12.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
13.
NgA, ChewI, NarasimhaluK, KandiahN (2013) Effectiveness of Montreal Cognitive Assessment for the diagnosis of mild cognitive impairment and mild Alzheimer’s disease in Singapore. Singapore Med J54, 616–619.
14.
VipinA, WongBYX, KumarD, LowA, NgKP, KandiahN (2021) Association between white matter hyperintensity load and grey matter atrophy in mild cognitive impairment is not unidirectional. Aging13, 10973–10988.
15.
Arevalo-RodriguezI, SmailagicN, RoquéIFM, CiapponiA, Sanchez-PerezE, GiannakouA, PedrazaOL, Bonfill CospX, CullumS (2015) Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2015, CD010783.
16.
Arevalo-RodriguezI, SmailagicN, Roqué-FigulsM, CiapponiA, Sanchez-PerezE, GiannakouA, PedrazaOL, Bonfill CospX, CullumS (2021) Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). , CD. Cochrane Database Syst Rev7, 010783.
17.
WangBZ, ZailanFZ, WongBYX, NgKP, KandiahN (2020) Identification of novel candidate autoantibodies in Alzheimer’s disease. Eur J Neurol27, 2292–2296.
